Marinomed Biotech AG
Develops treatments for viral infectious diseases and immunological disorders.
MARI | VI
Overview
Corporate Details
- ISIN(s):
- ATMARINOMED6
- LEI:
- 529900GN3B1EN80XF405
- Country:
- Austria
- Address:
- Hovengasse 25, 2100 Korneuburg
- Website:
- https://www.marinomed.com/en
- Sector:
- Manufacturing
Description
Marinomed Biotech AG is a biopharmaceutical company that develops medicinal products and medical devices for viral infectious diseases and immunological disorders. The company's innovation is driven by proprietary, patent-protected technology platforms. The Marinosolv platform enhances the solubility and bioavailability of poorly soluble compounds, enabling the development of treatments for immunological conditions such as allergies, asthma, and inflammatory diseases. The virology platform is the basis for therapies targeting viral respiratory infections. Marinomed maintains a development pipeline, has globally marketed therapeutics, and offers its technology through partnerships and services via its Solv4U unit.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-01-24 12:00 |
Marinomed Biotech AG: Simon Nebel, Erwerb: Erwerb der Aktien uber die engverbue…
|
German | 7.8 KB | ||
| 2025-01-21 14:30 |
Marinomed Biotech AG: Dr. Karl Mahler, buy
|
English | 7.3 KB | ||
| 2025-01-21 07:45 |
Marinomed Biotech AG: Restructuring proceedings successfully completed
|
English | 9.2 KB | ||
| 2025-01-20 14:31 |
EQS-DD: Marinomed Biotech AG: Dr. Karl Mahler, buy
|
English | 27.4 KB | ||
| 2025-01-20 14:31 |
EQS-DD: Marinomed Biotech AG: Dr. Karl Mahler, Kauf
|
German | 28.2 KB | ||
| 2025-01-20 14:30 |
Marinomed Biotech AG: Dr. Karl Mahler, buy
|
English | 7.3 KB | ||
| 2025-01-20 07:45 |
Marinomed Biotech AG: Restructuring proceedings successfully completed
|
English | 9.2 KB | ||
| 2025-01-01 10:00 |
Release according to Article 135, Section 1 BorseG with the objective of Europe…
|
English | 3.3 KB | ||
| 2024-12-31 14:08 | English | 13.8 KB | |||
| 2024-12-31 10:01 |
EQS-NVR: Marinomed Biotech AG: Release according to Article 135, Section 1 Börs…
|
English | 13.7 KB | ||
| 2024-12-31 10:01 |
EQS-NVR: Marinomed Biotech AG: Veröffentlichung der Gesamtstimmrechte nach § 13…
|
German | 14.1 KB | ||
| 2024-12-30 14:10 |
EQS-PVR: Marinomed Biotech AG: Release according to Article 135, Section 2 Börs…
|
English | 30.2 KB | ||
| 2024-12-30 14:10 |
EQS-PVR: Marinomed Biotech AG: Veröffentlichung gemäß § 135 Abs. 2 BörseG mit d…
|
German | 30.0 KB | ||
| 2024-12-30 14:08 | English | 13.8 KB | |||
| 2024-12-20 12:39 |
Marinomed Biotech AG: Extraordinary general meeting approves sale of Carragelos…
|
English | 9.7 KB |
Automate Your Workflow. Get a real-time feed of all Marinomed Biotech AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Marinomed Biotech AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Marinomed Biotech AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
